Author: Emma Hein

India’s pharma ascension: 20% of global generic drugs, 40% of US generic approvals. But 70% API import dependence on China defines the next decade.

Healthcare cyber crisis: 500+ ransomware attacks in 2024. Change Healthcare paid $22M ransom. Five board-level priorities hospital leadership must address.

Longevity economy: $27B invested since 2020. Altos Labs, Retro Biosciences, Calico shaping the category. ARPA-H commits $2.5B.

Value-based care crosses 50% Medicare Advantage penetration. Five forces rewriting healthcare business models — payers, providers, employers.

AI drug discovery: $50B in Big Pharma partnerships since 2022. Insilico, Recursion, Isomorphic compressing pharma timelines from decade to 18 months.

GLP-1 disruption beyond pharma: 12M Americans on Ozempic. Five industries — food, insurance, healthcare, consumer goods, telehealth — reshaped.

Carbon markets are now a $2 trillion infrastructure layer. Compliance markets are setting prices that affect corporate decisions; voluntary markets are recovering with stronger methodology. For carbon-exposed businesses, engagement is no longer optional.

ESG investing has reached a more sustainable equilibrium after the boom and backlash. The marketing category has receded; the substantive integration of environmental and social factors into investment has continued. Understanding the difference matters.

Feeding 8 billion people while managing climate stress and water scarcity is the food system’s defining challenge. Which agricultural and food technologies are delivering real impact — and which are still promising but unproven.

Sustainable businesses are outperforming on revenue growth, margins, and capital costs. The green premium is real, measurable, and earned through operational substance — not communications strategy.